These findings should jointly support our concept/conclusion that inhibition of TLR4/MyD88/NF-κB pathway activation may represent a major mechanism whereby dexmedetomidine reduces acute kidney injury after orthotopic autologous liver transplantation. The gene discussed is TLR4; the disease is acute kidney injury.